Japanese shares fall in early trading

October 7, 2008 05:03


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Japanese shares fell sharply in early trade Tuesday, briefly sending the country's benchmark index to its lowest level since December 2003. The Nikkei 225 was down 241.32 points, or 2.3 percent, at 10,231.77 near the close of morning trading. But earlier the index had tumbled over 5 percent to 9,916.21, dropping through the 10,000-barrier for the first time in almost five years. The drop came after global markets plunged overnight. The Dow Jones industrial average closed below 10,000 for the first time since 2004, and its fall was the dominant news story in papers and TV early Tuesday in Tokyo. Markets across Europe were also down heavily. The dollar continued to fall against the yen, trading near 101.53 yen versus 103 yen levels a day earlier.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection